Only patients at risk for developing pancreatic cancer because of their family history or because of a known genetic mutation associated with pancreatic cancer should be tested with the IMMray® PanCan-d test. This test should not be used as a general screening tool.
”The NCCN Pancreatic Adenocarcinoma Panel believes that decisions about diagnostic management and resectability of pancreatic cancer should involve multidisciplinary consultation at high-volume centers with use of appropriate imaging studies.” (NCCN Clinical Practice Guidelines. Pancreatic Ductal Adenocarcinoma, Version 2.2017)
Becker AE, Hernandez YG, Frucht H, Lucas AL. World J Gastroenterol. 2014;20(32):11182-11198.
Klein AP, Brune KA, Petersen GM et al. Cancer Res. 2004;64:2634-2638.
Schenk M, Schwartz AG, O’Neal E et al. J Natl Cancer Inst. 2001;93(8):640-644.
Lustgarten Foundation. “What is pancreatic cancer?” https://lustgarten.org/patient-journey/what-is-pancreatic-cancer/. (Accessed August 19, 2021).